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Comment on “A. annua and A. afra infusions vs. Artesunate-amodiaquine (ASAQ) in treating
Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial” Munyangi
et al., 2019
Dear Editor,
Introduction
We read with great interest the article entitled “A. annua and A. afra
infusions vs. Artesunate-amodiaquine (ASAQ) in treating Plasmodium
falciparum malaria in a large scale, double blind, randomized clinical
trial“ (Munyangi et al., 2019).
This study seems to be designed as a phase III double-blind rando-
mized clinical trial demonstrating the superiority of A. annua and A.
afra infusions over ASAQ for the treatment of uncomplicated P. falci-
parum malaria in Africa.
However, we have noticed some issues and inconsistencies in the
background, methods and results, and would like to provide the readers
of your journal with a critical analysis of this study. Indeed, we believe
that the scientific validity of the results is affected as well as the ethical
integrity given the lethal risk of malaria for infected patients.
Critical review of the article
Background
The clinical efficacy of Artemisia is not fully supported by the re-
ferences provided. The report of 18 malaria cases treated by dried leaf
of A. annua is biased as all patients received artesunate before A. annua
(Daddy et al., 2017). Consequently the attribution of recovery to A.
annua cannot be asserted. Of the four trials on Artemisia that are cited
the first one reports a 4-day parasitemia clearance rate of 44 / 48 (92%)
for A. annua infusion (Mueller et al., 2000). The second reference, is not
a clinical trial but rather a survey with retrospective declarative reports
of efficacy by patients themselves (Tiruneh et al., 2010). The third re-
ference (Chougouo-Kengne et al., 2012) describes a poorly reported 4-
group randomized controlled trial with many inconsistent results
showing 18 successes in 18 patients after 7 days of treatment with A.
annua tea infusions but an average parasitemia equal to 500 tropho-
zoites/µl at 7 days and 100 trophozoites/µl at 14 days in this group. The
fourth reference (Zime-Diawara et al., 2015) describes a non-controlled
trial of 12 g/day infusions of A. annua with a high cure rate (100%
parasite clearance in 108 patients after 28 days). Such a miraculous
clearance rate has never been observed even with the most efficient
drugs. Also there are strange results with 100% of patients with a body
temperature exactly equal to 37 °C from D3 to D28 which is unlikely to
occur in real life.
Better trials have been performed but none have supported the ef-
ficacy of Artemisia infusions. Mueller et al. (2004) tested the in vivo
efficacy of A. annua infusions vs. Quinine in a randomized controlled
trial, including 45 patients assigned to three groups: 5 g herb/day, 9 g
herb/day and Quinine 1500mg/day. The 7-day cure rates were re-
spectively 77%, 70% and 91% while the 30-day cure rates were 34%,
28% and 79%. Therefore, the authors raised concerns about the poor
efficacy of A. annua infusions and the risk of resistance due to the in-
sufficient dose of Artemisinin contained in A. annua. A randomized
controlled trial was conducted in Tanzania by Blanke et al. (2008)
between September 2002 and October 2003 but was discontinued early
because of the poor efficacy of A. annua infusions with a 28-day efficacy
rate of 10% (1/10) probably due to recrudescences.
Ethics
There are some ethical concerns. First a large-scale randomized
controlled trial for Artemisia (phase III) should not have been conducted
without prior evidence of efficacy in smaller randomized trials (e.g.,
phase IIb). Mueller et al. (2004) showed that 10 g/day of dried leaf of A.
annua was not enough to control the disease (recrudescence); the cur-
rent study protocol uses half the dose (5 g/day).
All treatments were started from D1, as specified in the Methods
section. Since the baseline is D0, as seen in tables, figures and text, this
implies that patients had to wait until the next day to receive their first
Malaria medication even though malaria is a life-threatening disease.
Indeed, malaria treatment should have been started as soon as possible,
just after randomization. In addition, patients were reportedly diag-
nosed with fever and parasitemia repeatedly over the duration of
follow-up (at D7, D14 and D28) but no rescue treatment was provided
to these persons.
We would like to point out that the same authors recently published
in your journal (Munyangi et al., 2018) another large-scale double blind
randomized controlled trial on Artemisia vs. praziquantel for the treat-
ment of schistosomiasis. We also found scientific and ethical issues, in
this previous article and sent a comment to your journal (Argemi et al.,
2019). We noticed that the article on schistosomiasis referred to the
same ethics committee registration number as the malaria article:
MIN.RST/SG/180/001/2016. Since the two protocols are very different
and cannot be applied to the same patients, it is hardly conceivable that
the same registration number could apply to both studies. Moreover
both studies were conducted in 2015 while the registration number
suggests that approval was obtained in 2016.
Methods
The study design has several issues. The randomization procedure is
unclear or inadequate. Envelope randomization assumes that envelopes
are given in the order patients are included but authors specify that
patients randomly selected an envelope. This makes stratified rando-
mization impossible and envelope tracking harder. The authors specify
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that the drugs were contained in an envelope. This is strange, but not
impossible when drugs provided for 7 days do not have a large volume.
However, since the Artemisia placebos were infusions of 0.2 g/day of
the plant, the number or size of Artemisia leaves would have been very
different between arms and the physician looking at the size of the
envelope would have been able to identify the group as well as the
patient. There are also concerns about the similarity of presentation
between the ASAQ placebo (purchased in “a pharmacy”) and the real
ASAQ Winthrop, Sanofi-Aventis. Obtaining visually identical placebo
usually requires a specific pharmaceutical preparation.
The study protocol mentions that all patients, with non-severe ma-
laria, were hospitalized for 7 days in order to ensure therapeutic
compliance. The list of hospital centers was not specified. Direct de-
livery of drugs to the patient in envelopes seems to be useless when
nurses could have provided the treatment during hospitalization. In the
ASAQ group, the active drug was given for 3 days, followed by 4 days of
placebo, without any clear reason for giving a placebo. Patients with
persistent vomiting were excluded; this may have caused an attrition
bias.
Neither a primary outcome nor a primary analysis was mentioned in
the Methods section. In the results section it was stated that “The pri-
mary outcome of the trial was that, based on microscopic analyses, both
Artemisia sp. cured malaria faster and more effectively than ASAQ”, but
no numeric results and no P-values were given. The analyses supporting
the statement “faster and more effectively” are not specified in the
methods. Since there are two Artemisia arms, multiple comparisons
should have been performed, with a multiple testing procedure ad-
justment to control the family-wise error rate. There is no sample size
calculation mentioned. Hypothesis test statistics are mandatory for a
clinical trial but descriptive results alone are provided by authors for
major outcomes such as parasitemia.
Results
Frequencies
Results are strange and inconsistent. Why was the number of
screened patients exactly equal to 2000? Why were the numbers of
included patients, at the same time, multiples of hundred in all centers
but one? If each center had been given instructions to stop screening
when a given number of patients was screened, that could explain why
the number of screened patients was a multiple of hundred, but would
not explain why numbers of included patients were multiples of hun-
dred and vice versa.
Sample sizes are inconsistent. The flow chart shows 957 randomized
patients at baseline but supplementary Table S1 shows 1000 rando-
mized patients. The flow chart shows 229 patients randomized in the A.
afra group but Table 5 shows 249 patients at D28 which means that 20
patients were gained during follow-up, a rather unusual situation.
Loss to follow-up shown in Fig. 1 (flow-chart) was 1.7% in pooled
Artemisia groups and 1.3% in the ASAQ group, but in Fig. 2 it was
10.3%, 26.7% and 0.0% in the A. annua, A. afra and ASAQ groups,
respectively.
Fever
In the summary, fever clearance was evaluated at 48 h for ASAQ and
24 h for Artemisia groups. Conversely, in the results section, the lower
panel of Fig. 2 shows that, at 7 days, fever persisted for 50% of patients
in the ASAQ and A. afra groups. The upper panel of Fig. 2 shows an
average temperature below 37 °C in the A. afra group at 7 days, which is
hardly compatible with 50% of patients having fever as shown in the
lower panel.
Trophozoite clearance
In the summary, trophozoites were cleared within 24 h in Artemisia
groups and 14 days in the ASAQ group. This contradicts the lower panel
of Fig. 3, showing more than 80% of patients with parasites at D7 in all
groups. The upper panel of Fig. 3 shows an average number of tro-
phozoites / µl equal or very close to 0 at 24 h in the A. annua group, in
contradiction with the lower panel showing fewer than 20% of negative
patients at that time.
The low response rate (34%) and the delayed response (14 days)
shown in Fig. 3 for ASAQ does not match the literature on this treat-
ment. In a recent (2013–2014) study conducted in South Kivu, a region
near to Kalima health district, the absolute parasitological cure rate of
ASAQ was about 91.6% (109 / 119) at D28 without Polymerase Chain
Reaction (PCR) correction for reinfections and 97.5% (116 / 119) with
PCR correction (Wit et al., 2016). With ASAQ, parasite clearance is
expected in less than three days (Dorkenoo et al., 2016)
World Health Organization (WHO) guidelines (Methods for
Surveillance of Antimalarial Drug Efficacy, 2009) recommend the eva-
luation of the PCR adjusted cure rate, which requires collecting geno-
type evidence to estimate if an infection identified post-treatment is a
recrudescence (an infection caused by the same parasite as identified
before treatment) interpreted as a failure or a reinfection (caused by a
parasite with a different genotype). Surprisingly, the authors report that
no sample could be exploited out of several thousand filter paper
samples that should have been collected.
Microscopy results suggest that detection of trophozoites might
have been insufficiently sensitive across the study. In the ASAQ arm,
161 patients displayed no parasites at D14. The same number of pa-
tients displayed no parasites at D28. This shows that no patient had any
reinfection or recrudescence between D14 and D28 or that an equal
number of patients had reinfection/recrudescence and delayed cure. A
similar absence or very low rate of reinfection is reported in the other
two arms. In high malaria transmission areas such as the Democratic
Republic of Congo, these results are highly unusual and contrast with
the study in South Kivu (Wit et al., 2016), showing a PCR-unadjusted
cure rate equal to 91.6% with ASAQ at D28 and 97.5% after PCR-ad-
justment, indicating that the majority of parasitemias observed after
treatment were caused by reinfections.
The authors stated that “By the log-rank test at D28, three of the
four compared groups were significantly different, but there was no
significant difference between A. annua and A. afra (p= 0.505)”. First,
log-rank test is not appropriate to compare rates at one time point, here
D28. Second, in the methodology, only three groups are presented, not
four.
There is also considerable heterogeneity in efficacy of treatments
between study sites, ranging from 0% (Kamundala) to 100% (Lubile)
negative parasitemia at D28 for ASAQ and from 0% (Kinkungwa, n=7)
to 100% (Kakutya) for A. afra.
Hemoglobin levels
Hemoglobin levels are said to be non-significantly different at D0,
D1, D3 and D4 between A. annua and ASAQ groups. This contradicts the
data in Fig. 5. Indeed, Fig. 5 shows whiskers that may either be con-
fidence intervals or standard errors (not specified by authors). Even in
case of standard errors, the difference at D0 between ASAQ and A.
annua would have been statistically significant. Indeed, doubling width
of whiskers could provide confidence intervals that do not overlap at
all. A statistically significant difference at D0 (baseline) suggests that
the randomization protocol was not properly conducted.
Adverse effects
Table 4 shows adverse effects. Both Artemisia arms were pooled. The
very low level of adverse effects in the Artemisia arms suggests a dif-
ferential declaration bias, since non-specific symptoms such as asthenia
should have been found in more than four hundred patients followed
for 28 days (more than eleven thousand patient-days). This is only
possible if the blinding was broken. The difference between adverse
effects (attributed to treatment) and adverse events (not necessarily
attributed to treatment) was not made. Strangely, numbers of adverse
effects were mostly multiples of five, as 10 in 13 frequencies of non-zero
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Fig. 1. Trial design.
Fig. 2. Average fever progression among the three treatment arms. Top, graphical representation. Bottom, Kaplan–Meier; survival time of fever started when a
patient was included in the study (D0). Patients were followed until D28. For patients withdrawing from the study before D28 or still having fever until D28, survival
time is said to be censored. The survival probability was calculated using the Kaplan–Meier method. The censored rates of A. annua, A. afra, and ASAQ are 0.0%,
10.3%, and 26.7%, respectively, with p-value of log-rank still near to zero and statistically significant.
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side effects were multiples of five. Comparison with the theoretical
value of 20% yields a P-value of 1.6×10−5, showing that this cannot
be explained by random fluctuations.
Randomization
In the appendix, table S1 shows baseline clinical symptoms in two
groups. Although there are actually three groups, both Artemisia groups
were pooled. Table S1 shows more patients than were randomized ac-
cording to Fig. 1 in the main body of the article. Moreover, the differ-
ences between groups were smaller than expected by random fluctua-
tions. A chi-square test on this table yields a P-value equal to 0.958,
meaning that randomization had a less than 5% chance of providing a
difference as small as or smaller than the actual difference observed
between groups. Unless minimization randomization was used on
symptoms, this excellent balance cannot be explained; but minimiza-
tion randomization cannot be performed in envelopes. Table 1 shows an
unbalanced distribution of age that is incompatible with a proper ran-
domization procedure. Indeed there are 102 (41.1%) children 6–15
years old in the A. annua group, compared to 51 (22.9%) in the A. afra
group and 105 (22.3%) in the ASAQ group which is highly significant
(p=10−7 for a chi-square test). Out of 300 patients randomized on the
Kinkungwa site only seven were randomized in the A. afra arm ac-
cording to the footnote of Table 2, while 75 were expected. This cannot
be explained by random fluctuations (binomial test p < 10−26).
Fig. 3. Average parasitemia progression among the three treatment arms. Top, graphical representation. Bottom, Kaplan–Meier; survival time of parasites started
when a patient was included in the study (D0). Patients were followed until D28. For patients withdrawing from the study before D28 or still having parasites until
D28, survival time is said to be censored. The censored survival rates of A. annua, A. afra, and ASAQ are 3.6%, 11.2%, and 65.7%, respectively.
Fig. 4. Microscopically determined proportion of patients with gametocytes (carriers) throughout the trial period.
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Baseline data by study site
Table 2 shows the characteristics of patients at baseline and D28 in
the five study sites. Some data are not shown as some variables were
“not measured” (nm) according to authors. Age was not measured in
Kamundala in the A. afra group but was measured in the A. annua and
ASAQ groups. How can some core baseline variables be collected in
some randomization arms but not in others in a double blind rando-
mized controlled trial? Age must be collected before randomization.
The same problem applies to parasitemia (trophozoites/µl) at D0 and
D28. The handling of these missing data on a major outcome is never
described: were these patients excluded for parasitemia analyses)?
Summary
In summary the critical analysis of this clinical trial shows im-
portant ethical issues, major concerns about methodology and highly
Fig. 5. Hemoglobin levels during the first four days of treatment.
Table 1
Demographics of the Artemisia and ASAQ trial arms at time of enrollment (D0).
Treatment arm Gender Age
Male (%) Female (%) ≤ 5 y 6–15 y (%) > 15 y (%)
A. annua 168 (67.7%) 80 (32.3%) 0 102 (41.1%) 146 (58.9%)
A. afra 158 (70.9%) 65 (29.1%) 0 51 (22.9%) 172 (77.1%)
ASAQ 308 (65.3%) 164 (34.7%) 0 105 (22.3%) 367 (77.7%)
Table 2
Average and median patient age and parasite levels at the five study sites at D0 and D28.
Arm Median (y) Site average patient age (y)
Kakutya Kinkungwa Kamundala Lubile Kakozwa
A. annua 19 22 25 24 nm 20
A. afra 25 28 27.5 nm 26.5 13.5
ASAQ 29 33 29.5 32 23 21
Overall 26 26 28.5 28 25 19.5
Median parasites D0 mean/site (trophozoites/μl)
A. annua 42,426 40,632 36,120 ≥ 50,000a nm ≥ 50,000a
A. afra 33,911 39,860 39,150 nm 29,617 ≥ 50,000a
ASAQ 43,018 38,702 42,106 ≥ 50,000a 39,915 ≥ 50,000a
% parasites D28 mean/site (trophozoites/μl)
A. annua na 91%=0 100%=0 100%=0 nm 100%=0
9% ≤ 10
A. afra na 100%=0 100% ≤ 10b nm 100%=0 92%=0
8% ≤ 10
ASAQ na 93%=0 6%=0 100% ≤ 10 100%=0 38% ≤ 10
7% ≤ 10 84% ≤ 10 62% ≥ 10,000
10% ≥ 10,000
Not all test sites included both Artemisias; na, not applicable; nm, not measured at that site.
a Parasites were not enumerated beyond 50,000.
b There were only 7 A. afra patients in this arm at this site.
Table 3
Cure rates by age group within each trial arm at D14 and 28.
Age (y) D14 D28
A. annua A. afra ASAQ A. annua A. afra ASAQ
n/Na (%)b n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
5–15 93/102 36/51 51/105 93/102 42/51 52/105
(91.2%) (70.6%) (48.6%) (91.2%) (82.4%) (49.5%)
16–65 146/146 145/172 110/367 146/146 156/172 110/367
(100.0%) (84.3%) (30.0%) (100.0%) (90.7%) (30.0%)
Overall 239/248 181/223 161/472 239/248 198/223 162/472
(96.4%) (81.2%) (34.1%) (96.4%) (88.8%) (34.3%)
a N, total number within age group less any who left the trial; n, number with
0 parasitemia.
b (%), n/N×100.
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discordant results. No large-scale clinical randomized trial should have
been performed with A. afra infusions, which have not shown con-
sistent in vivo efficacy against P. falciparum. Moreover cases of severe
malaria have already been reported in travelers receiving A. annua as
chemoprophylaxis (Lagarce et al., 2016). Failure of chemoprophylaxis
does not support the use of the same drug in the treatment of malaria.
Inconsistencies and methodology issues call into question the results of
this trial. In light of these discordant results, ACT should remain the
first treatment of uncomplicated P. falciparum malaria.
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Table 4
Distribution among patients of adverse effects from treatment.
Observed adverse effects Number of subjects in the
Artemisia arms
Number of subjects in
the ASAQ arm
Abdominal pain 0 25
Asthenia 0 30
Diarrhea 0 5
Drowsiness 0 3
Fatty cough 0 1
Hypoglycemia 0 20
Insomnia 0 10
Nausea 10 30
Pruritis 0 35
Vertigo 0 1
Vomiting 15 50
Total 25 210
% of total 5.0% 42.8%
Table 5
Level of microscopically determined gametocyte carriage decrease D14–28
within age groups.
Age (y) A. annua n/N (%) A. afra n/N (%) ASAQ n/N (%)
Children (5–15) 43/43 (100%) 102/102 (100%) 111/114 (97.4%)
Adults (16–65) 205/205 (100%) 147/147 (100%) 369/376 (98.1%)
Total 248/248 (100%) 249/249 (100%) 480/490 (98.0%)
N, total within age group; n, number of patients with microscopically un-
detectable gametocytes.
⁎ Corresponding author.
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